Comments
Loading...

UroGen Pharma

URGNNASDAQ
Logo brought to you by Benzinga Data
$13.67
0.574.33%
Pre-Market: 5:22 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$60.00
Lowest Price Target1
$10.00
Consensus Price Target1
$34.50

UroGen Pharma (NASDAQ:URGN) Stock, Analyst Ratings, Price Targets, Forecasts

UroGen Pharma Ltd has a consensus price target of $34.5 based on the ratings of 7 analysts. The high is $60 issued by HC Wainwright & Co. on August 15, 2024. The low is $10 issued by Jefferies on February 8, 2023. The 3 most-recent analyst ratings were released by Guggenheim, HC Wainwright & Co., and HC Wainwright & Co. on August 22, 2024, August 15, 2024, and August 14, 2024, respectively. With an average price target of $53.33 between Guggenheim, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 290.22% upside for UroGen Pharma Ltd from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Apr
1
May
1
Jun
0
0
0
0
Jul
0
0
0
0
Aug
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Guggenheim
HC Wainwright & Co.
Ladenburg Thalmann
Oppenheimer
Goldman Sachs

1calculated from analyst ratings

Analyst Ratings for UroGen Pharma

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for UroGen Pharma (URGN) stock?

A

The latest price target for UroGen Pharma (NASDAQ:URGN) was reported by Guggenheim on August 22, 2024. The analyst firm set a price target for $40.00 expecting URGN to rise to within 12 months (a possible 192.66% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for UroGen Pharma (URGN)?

A

The latest analyst rating for UroGen Pharma (NASDAQ:URGN) was provided by Guggenheim, and UroGen Pharma initiated their buy rating.

Q

When was the last upgrade for UroGen Pharma (URGN)?

A

There is no last upgrade for UroGen Pharma

Q

When was the last downgrade for UroGen Pharma (URGN)?

A

The last downgrade for UroGen Pharma Ltd happened on February 8, 2023 when Jefferies changed their price target from $35 to $10 for UroGen Pharma Ltd.

Q

When is the next analyst rating going to be posted or updated for UroGen Pharma (URGN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of UroGen Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for UroGen Pharma was filed on August 22, 2024 so you should expect the next rating to be made available sometime around August 22, 2025.

Q

Is the Analyst Rating UroGen Pharma (URGN) correct?

A

While ratings are subjective and will change, the latest UroGen Pharma (URGN) rating was a initiated with a price target of $0.00 to $40.00. The current price UroGen Pharma (URGN) is trading at is $13.67, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.